Sunday, December 22, 2024

Healthcare

NurExone Biologic Inc. Accelerates Growth with Dr. Yona Geffen’s Expertise (TSXV: NRX, OTCQB: NRXBF)

NurExone Biologic Inc TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90 is a pioneering...

NurExone’s Game-Changing Moves in Biopharmaceuticals and Exosome Technology (TSXV: NRX, OTCQB: NRXBF, FSE: J90, NRX.V)

NurExone (TSXV: NRX) (Germany: J90)  (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies. For a quick catch up on NRX, here are...

Exploring RenovoRx’s Breakthroughs in Targeted Cancer Treatments

RenovoRx’s TAMP™ platform significantly increases local tissue concentration of chemotherapy, potentially reducing systemic side effects and enhancing treatment efficacy. The Phase III TIGeR-PaC clinical trial...

RenovoRx’s TAMP Platform Revolutionizes Cancer Therapy (Nasdaq: RNXT)

 ("RenovoRx" or the "Company") (Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform.  Recently, the Company announced the...

NurExone’s Expands Commercialization Efforts with All-star Hire (TSXV: NRX)

NurExone (TSXV: NRX) (Germany: J90)  (the “Company” or “NurExone") is a pioneering biopharmaceutical company developing regenerative medicine therapies. For a quick catch up on NRX, here are...

Popular

Subscribe